Landscape Capital Management L.L.C. Makes New $4.14 Million Investment in Lantheus Holdings Inc (NASDAQ:LNTH)

Landscape Capital Management L.L.C. acquired a new position in shares of Lantheus Holdings Inc (NASDAQ:LNTH) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 146,214 shares of the medical equipment provider’s stock, valued at approximately $4,138,000. Landscape Capital Management L.L.C. owned approximately 0.38% of Lantheus as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. LSV Asset Management increased its position in shares of Lantheus by 2.1% during the first quarter. LSV Asset Management now owns 1,633,414 shares of the medical equipment provider’s stock worth $39,985,000 after acquiring an additional 33,882 shares in the last quarter. Vaughan Nelson Investment Management L.P. grew its position in Lantheus by 5.6% in the first quarter. Vaughan Nelson Investment Management L.P. now owns 1,587,904 shares of the medical equipment provider’s stock valued at $38,872,000 after purchasing an additional 84,529 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Lantheus by 5.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,379,017 shares of the medical equipment provider’s stock valued at $21,581,000 after purchasing an additional 65,609 shares in the last quarter. JPMorgan Chase & Co. grew its position in Lantheus by 41.7% in the second quarter. JPMorgan Chase & Co. now owns 1,034,497 shares of the medical equipment provider’s stock valued at $28,584,000 after purchasing an additional 304,537 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Lantheus by 15.3% in the fourth quarter. Geode Capital Management LLC now owns 428,939 shares of the medical equipment provider’s stock valued at $6,712,000 after purchasing an additional 56,935 shares in the last quarter. 91.35% of the stock is owned by institutional investors.

In other Lantheus news, SVP Michael P. Duffy sold 8,819 shares of the business’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $28.14, for a total value of $248,166.66. Following the completion of the transaction, the senior vice president now owns 144,494 shares of the company’s stock, valued at approximately $4,066,061.16. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Derace L. Schaffer sold 20,000 shares of the business’s stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $23.82, for a total value of $476,400.00. Following the completion of the transaction, the director now directly owns 36,994 shares of the company’s stock, valued at approximately $881,197.08. The disclosure for this sale can be found here. In the last three months, insiders sold 136,187 shares of company stock valued at $3,604,063. 2.60% of the stock is owned by insiders.



Shares of NASDAQ LNTH traded up $0.18 during mid-day trading on Thursday, reaching $21.48. 6,706 shares of the company were exchanged, compared to its average volume of 491,893. The firm’s 50-day moving average is $25.84. The company has a debt-to-equity ratio of 2.05, a current ratio of 2.62 and a quick ratio of 2.01. The company has a market capitalization of $863.75 million, a PE ratio of 22.81, a P/E/G ratio of 1.76 and a beta of 1.47. Lantheus Holdings Inc has a twelve month low of $12.59 and a twelve month high of $29.80.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, July 25th. The medical equipment provider reported $0.27 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.27. Lantheus had a return on equity of 51.08% and a net margin of 11.20%. The business had revenue of $85.70 million during the quarter, compared to analyst estimates of $88.72 million. During the same quarter in the previous year, the firm earned $0.25 EPS. Lantheus’s revenue was up .1% on a year-over-year basis. As a group, analysts expect that Lantheus Holdings Inc will post 1.06 earnings per share for the current fiscal year.

A number of research analysts recently weighed in on LNTH shares. ValuEngine downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Zacks Investment Research downgraded shares of Lantheus from a “hold” rating to a “sell” rating in a research report on Friday, August 2nd. Finally, BidaskClub downgraded shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 11th.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Recommended Story: Special Dividends

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings Inc (NASDAQ:LNTH).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.